State Street’s Adial Pharmaceuticals ADIL Stock Holding History

State Street’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-84	Closed	-$10.9K	–	4555
2023 Q2	$10.9K	Hold	84	–	–	﹤0.01%	4641
2023 Q1	$18.3K	Hold	84	–	–	﹤0.01%	4693
2022 Q4	$11.2K	Hold	84	–	–	﹤0.01%	4794
2022 Q3	$18K	Hold	84	–	–	﹤0.01%	4841
2022 Q2	$70K	Hold	84	–	–	﹤0.01%	4648
2022 Q1	$105K	Buy	84 +4	+5%	+$5.48K	﹤0.01%	4625
2021 Q4	$135K	Hold	80	–	–	﹤0.01%	4499
2021 Q3	$215K	Buy	80 +2	+3%	+$4.19K	﹤0.01%	4331
2021 Q2	$125K	Buy	+78	New	+$119K	﹤0.01%	4325

Other funds holding ADIL

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AWM

Abound Wealth Management Franklin, Tennessee $504M AUM 23.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

State Street's ADIL Position: Q3 2023 in Review

State Street sold out of Adial Pharmaceuticals (ADIL) in Q3 2023, closing a stake of 84 shares — an estimated $10.9K sold.

State Street first reported a position in ADIL in Q2 2021 and held it in 9 quarters. The position peaked at $215K in Q3 2021. 8 funds tracked by Wall St. Rank hold ADIL as of Q3 2023.

State Street reported no remaining Adial Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
State Street sold 84 Adial Pharmaceuticals shares in Q3 2023, an estimated $10.9K.
State Street first reported a position in Adial Pharmaceuticals in Q2 2021 and held it in 9 quarters.
State Street's Adial Pharmaceuticals position peaked at $215K in Q3 2021.
8 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.